
Methotrexate >15 mg weekly and adalimumab as first-line therapy were positive predictors of anti-TNF-a response in patients with rheumatoid arthritis.
Methotrexate >15 mg weekly and adalimumab as first-line therapy were positive predictors of anti-TNF-a response in patients with rheumatoid arthritis.
Published: July 1st 2009 | Updated: